|
154
|
548
|
5cyqA |
Hiv-1 reverse transcriptase complexed with 4-bromopyrazole |
|
20
|
99
|
4yhqA |
Crystal structure of multidrug resistant clinical isolate pr20 with grl-5010a |
|
151
|
556
|
5cymA |
Hiv-1 reverse transcriptase complexed with 4-iodopyrazole |
|
117
|
424
|
5cyqB |
Hiv-1 reverse transcriptase complexed with 4-bromopyrazole |
|
16
|
99
|
5agzA |
Disubstituted bis-thf moieties as new p2 ligands in non-peptidal hiv- 1 protease inhibitors (ii) |
|
17
|
99
|
5ahaA |
Disubstituted bis-thf moieties as new p2 ligands in non-peptidal hiv- 1 protease inhibitors (ii) |
|
17
|
99
|
5ahbA |
Disubstituted bis-thf moieties as new p2 ligands in non-peptidal hiv- 1 protease inhibitors (ii) |
|
19
|
99
|
4ye3A |
Crystal structure of multidrug resistant hiv-1 protease clinical isolate pr20 with inhibitor grl-4410a |
|
16
|
99
|
5ahcA |
Disubstituted bis-thf moieties as new p2 ligands in non-peptidal hiv- 1 protease inhibitors (ii) |
|
16
|
99
|
5ah6A |
Disubstituted bis-thf moieties as new p2 ligands in non-peptidal hiv- 1 protease inhibitors (ii) |
|
18
|
99
|
5ah9A |
Disubstituted bis-thf moieties as new p2 ligands in non-peptidal hiv- 1 protease inhibitors (ii) |
|
16
|
99
|
5ah8A |
Disubstituted bis-thf moieties as new p2 ligands in non-peptidal hiv- 1 protease inhibitors (ii) |
|
16
|
99
|
5ah7A |
Disubstituted bis-thf moieties as new p2 ligands in non-peptidal hiv- 1 protease inhibitors (ii) |
|
106
|
425
|
4we1B |
Crystal structure of hiv-1 reverse transcriptase in complex with 5-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)ethoxy)phenoxy)-2-naphthonitrile (jlj600) |
|
140
|
547
|
4we1A |
Crystal structure of hiv-1 reverse transcriptase in complex with 5-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)ethoxy)phenoxy)-2-naphthonitrile (jlj600) |
|
66
|
220
|
4wymA |
Structural basis of hiv-1 capsid recognition by cpsf6 |
|
17
|
99
|
4upjA |
Human immunodeficiency virus type 2 protease mutant with lys 57 replaced by leu (k57l) complex with u097410 [4-hydroxy-3-[1-[3-[[[[(tert-butyloxycarbonyl) aminomethyl]carbonyl]amino]phenyl]propyl]coumarin |
|
18
|
99
|
4u7qA |
Structure of wild-type hiv protease in complex with photosensitive inhibitor pdi-6 |
|
136
|
548
|
4rw8A |
Crystal structure of hiv-1 reverse transcriptase in complex with (e)-3-(3-chloro-5-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)ethoxy)phenoxy)phenyl)acrylonitrile (jlj532), a non-nucleoside inhibitor' |
|
18
|
99
|
4u7vA |
Structure of wild-type hiv protease in complex with degraded photosensitive inhibitor |
|
0
|
9
|
4u1jC |
Hla class i micropolymorphisms determine peptide-hla landscape and dictate differential hiv-1 escape through identical epitopes |
|
138
|
554
|
4rw9A |
Crystal structure of hiv-1 reverse transcriptase (y181c) variant in complex with (e)-3-(3-chloro-5-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)ethoxy)phenoxy)phenyl)acrylonitrile (jlj532), a non-nucleoside inhibitor |
|
102
|
424
|
4rw7B |
Crystal structure of hiv-1 reverse transcriptase (k103n, y181c) variant in complex with (e)-3-(3-chloro-5-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)ethoxy)phenoxy)phenyl)acrylonitrile (jlj532), a non-nucleoside inhibitor |
|
110
|
424
|
4rw4B |
Crystal structure of hiv-1 reverse transcriptase (k103n,y181c) variant in complex with (e)-3-(3-chloro-5-(4-chloro-2-(2-(2,4-dioxo-3,4- dihydropyrimidin-1(2h)-yl)ethoxy)phenoxy)phenyl)acrylonitrile (jlj494), a non-nucleoside inhibitor |
|
138
|
554
|
4rw7A |
Crystal structure of hiv-1 reverse transcriptase (k103n, y181c) variant in complex with (e)-3-(3-chloro-5-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)ethoxy)phenoxy)phenyl)acrylonitrile (jlj532), a non-nucleoside inhibitor |
|
146
|
554
|
4rw6A |
Crystal structure of hiv-1 reverse transcriptase (y181c) variant in complex with (e)-3-(3-chloro-5-(4-chloro-2-(2-(2,4-dioxo-3,4- dihydropyrimidin-1(2h)-yl)ethoxy)phenoxy)phenyl)acrylonitrile (jlj494), a non-nucleoside inhibitor |
|
110
|
427
|
4rw8B |
Crystal structure of hiv-1 reverse transcriptase in complex with (e)-3-(3-chloro-5-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)ethoxy)phenoxy)phenyl)acrylonitrile (jlj532), a non-nucleoside inhibitor' |
|
145
|
554
|
4rw4A |
Crystal structure of hiv-1 reverse transcriptase (k103n,y181c) variant in complex with (e)-3-(3-chloro-5-(4-chloro-2-(2-(2,4-dioxo-3,4- dihydropyrimidin-1(2h)-yl)ethoxy)phenoxy)phenyl)acrylonitrile (jlj494), a non-nucleoside inhibitor |
|
109
|
424
|
4rw9B |
Crystal structure of hiv-1 reverse transcriptase (y181c) variant in complex with (e)-3-(3-chloro-5-(2-(2-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)ethoxy)phenoxy)phenyl)acrylonitrile (jlj532), a non-nucleoside inhibitor |
|
111
|
424
|
4rw6B |
Crystal structure of hiv-1 reverse transcriptase (y181c) variant in complex with (e)-3-(3-chloro-5-(4-chloro-2-(2-(2,4-dioxo-3,4- dihydropyrimidin-1(2h)-yl)ethoxy)phenoxy)phenyl)acrylonitrile (jlj494), a non-nucleoside inhibitor |
|
19
|
99
|
4u8wA |
Hiv-1 wild type protease with grl-050-10a (a gem-difluoro-bis-tetrahydrofuran as p2-ligand) |
|
17
|
99
|
4qj8A |
Crystal structure of inactive hiv-1 protease variant (i50v/a71v) in complex with p1-p6 substrate variant (p453l) |
|
20
|
99
|
4qj9A |
Crystal structure of inactive hiv-1 protease in complex with p1-p6 substrate variant (r452s) |
|
17
|
99
|
4qj6A |
Crystal structure of inactive hiv-1 protease variant (i50v/a71v) in complex with p1-p6 substrate variant (l449f) |
|
18
|
99
|
4qj7A |
Crystal structure of inactive hiv-1 protease variant (i50v/a71v) in complex with p1-p6 substrate variant (r452s) |
|
76
|
219
|
4qnbA |
Disulfide stabilized hiv-1 ca hexamer in complex with phenyl-l-phenylalaninamide inhibitor |
|
17
|
99
|
4q1yA |
Mutations outside the active site of hiv-1 protease alter enzyme structure and dynamic ensemble of the active site to confer drug resistance |
|
40
|
133
|
4qagA |
Structure of a dihydroxycoumarin active-site inhibitor in complex with the rnase h domain of hiv-1 reverse transcriptase |
|
15
|
99
|
4phvA |
X-ray crystal structure of the hiv protease complex with l-700,417, an inhibitor with pseudo c2 symmetry |
|
19
|
99
|
4qgiA |
X-ray crystal structure of hiv-1 protease variant g48t/l89m in complex with saquinavir |
|
18
|
99
|
4q1xA |
Mutations outside the active site of hiv-1 protease alter enzyme structure and dynamic ensemble of the active site to confer drug resistance |
|
46
|
203
|
4q5mA |
D30n tethered hiv-1 protease dimer/saquinavir complex |
|
50
|
151
|
4pa1A |
Crystal structure of catalytic core domain of fiv integrase |
|
18
|
99
|
4q1wA |
Mutations outside the active site of hiv-1 protease alter enzyme structure and dynamic ensemble of the active site to confer drug resistance |
|
18
|
99
|
4obhA |
Crystal structure of inactive hiv-1 protease in complex with the p1-p6 substrate variant (l449f) |
|
45
|
154
|
4o55A |
Hiv-1 integrase catalytic core domain complexed with allosteric inhibitor (2s)-tert-butoxy[6-(5-chloro-1h-benzimidazol-2-yl)-2,5-dimethyl-4-phenylpyridin-3-yl]ethanoic acid |
|
108
|
425
|
4ncgB |
Discovery of doravirine, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant hiv viruses |
|
140
|
552
|
4o44A |
Crystal structure of hiv-1 reverse transcriptase in complex with 4-((4-(mesitylamino)-6-(3-morpholinopropoxy)-1,3,5-triazin-2-yl)amino)benzonitrile (jlj529), a non-nucleoside inhibitor |
|
99
|
427
|
4o44B |
Crystal structure of hiv-1 reverse transcriptase in complex with 4-((4-(mesitylamino)-6-(3-morpholinopropoxy)-1,3,5-triazin-2-yl)amino)benzonitrile (jlj529), a non-nucleoside inhibitor |
|
47
|
145
|
4nx4C |
Re-refinement of cap-1 hiv-ca complex |
